Food-Drug Interactions on Drug Safety & Efficacy

The FDA’s guidance Assessing the Effects of Food on Drugs in INDs and NDAs- Clinical Pharmacology Considerations, emphasizes the importance of Food-Effect (FE) studies in assessing how food influences the absorption, safety, and effectiveness of orally administered drugs during drug development. Here’s a breakdown of key takeaways:

Why Food Effects Matter?

  • Food can alter drug absorption, impacting efficacy and safety.
  • High-fat meals generally have the greatest impact.
  • The goal: optimize safety and provide clear administration instructions.

When to Conduct Food Effects Studies?

FE studies should be initiated early during drug development. Initial pilot studies with high-fat meals provide preliminary insights, while definitive studies using the final drug formulation confirm the impact of food.

Study Requirements

  • FE studies required for new drug products (immediate/modified-release, fixed-combination).
  • Test with high-fat meals and consider low-fat meals if needed.
  • Pilot studies early in development help guide dosing strategy.

Study Design Considerations

  • Crossover designs (fed vs. fasted) are recommended.
  • Subject selection should include diverse groups, except where safety concerns exist.
  • Use clinically recommended doses unless contraindicated.

Data Analysis

  • PK parameters like AUC, Cmax, and Tmax are crucial for understanding food’s impact.

Labelling Implications

  • Labelling should clearly inform whether the drug should be taken with or without food based on these findings.
  • Example: “Take on an empty stomach at least 2 hours before or 1 hour after food.”
  • Example: “Take with a low-fat meal or on an empty stomach.”

Special Populations

  • Separate studies not required for geriatric patients.
  • Pediatric FE studies can be conducted in adults, with results extrapolated.

Innovative Approaches

  • The FDA may waive FE studies for Biopharmaceutics Classification System (BCS) Class 1 drugs due to minimal food impact.
  • Model-informed drug development approaches like PBPK modelling are encouraged to complement FE studies.


Read also:


Resource Person: Bhupesh Pratap

Leave a Comment